查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1834022

頭孢菌素類藥物市場按藥物類別、給藥途徑、劑型、最終用戶、通路和應用分類——2025 年至 2032 年全球預測

Cephalosporin Drugs Market by Drug Class, Route Of Administration, Dosage Form, End User, Distribution Channel, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年頭孢菌素藥物市場將成長 206 億美元，複合年成長率為 6.85%。

主要市場統計數據
基準年2024年 121.1億美元
預計2025年 129.5億美元
預測年份：2032年 206億美元
複合年成長率（%） 6.85%

在不斷變化的臨床標準、供應壓力和相關人員，頭孢菌素治療的策略框架

幾十年來，頭孢菌素類藥物一直是抗菌治療的基石，並不斷適應不斷變化的病原體易感性、臨床實踐和供應鏈現實。本導言將此類治療藥物置於當代新的監管預期、不斷演變的抗藥性模式以及不斷變化的給藥和配藥偏好的背景下進行闡述。透過組裝頭孢菌素類藥物置於這些相互交織的因素中，讀者將理解為何涵蓋藥物類別、給藥途徑、劑型、最終用戶環境、分銷管道和臨床用途的詳細資訊對於策略決策至關重要。

臨床相關人員越來越重視藥物管理，同時兼顧快速有效的治療需求。同時，製造商和經銷商面臨生產複雜性、原料限制和價格壓力等挑戰。政策制定者和付款人正在實施有針對性的干涉措施，這些措施會影響處方集的佈局、籌資策略和報銷結構。在此背景下，頭孢菌素類藥物並非一成不變，而是受到處方者行為、新出現的抗藥性以及決定藥物取得和使用的後勤因素的正面影響。

本引言闡明了研究範圍和所採用的分析視角，為後續分析奠定了基礎。它強調了整合臨床、商業和管理觀點以得出可操作結論的重要性。讀者可以綜合臨床證據、供應方動態和相關人員獎勵，為產品開發、產品組合管理和分銷策略的決策提供參考。

透過診斷、嚴格的監管和不斷發展的流通結構再形成頭孢菌素療法的關鍵變革力量

由於科學創新、抗生素管理監管格局以及整個醫藥供應鏈的結構性變化，頭孢菌素的格局正在發生重大變化。新的診斷工具和快速藥敏試驗正在影響醫療保健中的處方，使得頭孢菌素的使用更加精準，並在窄譜藥物足夠的情況下減少對經驗性廣譜頻譜的暴露。同時，有關抗生素管理指標和生產品管的法律規範正在加強，推動產業在合規性、可追溯性和批次保證方面的投資增加。

在商業方面，分銷模式正在發生變化，數位管道和專業物流加速了產品向門診手術中心、居家照護機構和分散診所的配送。對注射劑和粉劑低溫運輸及包裝的投資，與對支持門診護理的口服製劑的關注並存。這種轉變也與臨床實務息息相關：醫院會根據療效和供應彈性調整製劑，處方醫師在選擇藥物時會考慮當地的抗藥性模式。

綜上所述，這些變化正在重塑競爭動態，迫使現有企業重新思考其產品組合，並迫使新參與企業尋求利基配方和給藥系統。對於決策者而言，其影響顯而易見：在製造、監管和商業營運方面的適應性將決定誰能引領下一波臨床和物流需求。

不斷變化的美國關稅和貿易政策將如何對頭孢菌素供應鏈的彈性和籌資策略施加累積壓力

近期的關稅改革和貿易政策調整對藥品採購和分銷產生了顯著的連鎖反應，尤其對頭孢菌素類抗生素等供應鏈複雜的產品。影響原料藥和成品的關稅表變化可能會改變相對的採購經濟性，迫使製造商重新評估其供應商佈局，考慮將某些生產流程本地化，或調整其進出口策略，以減輕成本和前置作業時間的影響。

為此，製造外包和品牌所有者尋求替代籌資策略，包括多方採購、區域化供應流以及增加關鍵投入的庫存緩衝。物流合作夥伴被要求提高到岸成本和時間的透明度，以便採購團隊能夠基於場景制定決策，平衡成本、韌性和合規性。醫療保健提供者和集團採購組織都在重新評估供應商合約和交付條款，以保持住院和門診病人護理的連續性。

從臨床角度來看，關稅的間接影響將體現為製劑談判和採購時間表的變化，這可能會改變某些劑型和給藥途徑的供應模式。其累積效應是更注重供應鏈風險管理和採購敏捷性，相關人員將優先考慮那些能夠提供安全、合規且成本可預測的供應的合作夥伴。展望未來，將貿易政策意識融入產品生命週期規劃和籌資策略的組織將更有能力維持市場進入並有效管理單價波動。

整合多維細分，將藥物類別、給藥途徑、劑型、最終用戶行為、分銷管道和臨床使用聯繫起來

細緻的細分框架對於理解頭孢菌素類藥物的臨床需求、生產複雜性和分銷經濟性如何交匯至關重要。在藥物類別中，我們分析了第五代、第一代、第四代、第二代和第三代藥物，並詳細研究了第三代藥物：頭孢地尼、頭孢克肟、頭孢噻肟、頭孢他啶和頭孢曲松。這種按藥物類別細分的藥物揭示了不同的臨床作用，一些藥物在社區獲得性感染中保持主要效用，而另一些藥物則在院內感染和嚴重性行為感染中發揮重要作用。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 針對醫院環境中多重抗藥性革蘭氏陰性病菌感染的新興第五代頭孢菌素候選藥物
  • 製藥公司與生技Start-Ups之間的策略合作加速了新型頭孢菌素抗生素的發現
  • 較低的製造成本和監管支持推動亞太地區非專利頭孢菌素的生產
  • 整合抗生素管理計劃，最佳化頭孢菌素的使用並抑制抗生素抗藥性趨勢
  • 頭孢菌素和BETA-內醯胺酶抑制劑聯合治療，用於克服頻譜抗藥性菌株
  • 政府定價和報銷改革正在影響全球先進頭孢菌素治療的可近性和可負擔性。

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 頭孢菌素類藥物市場（依藥物類別）

  • 第五代
  • 第一代
  • 第四代
  • 第二代
  • 第三代
    • 頭孢地尼
    • 頭孢克肟
    • 頭孢噻肟
    • 頭孢他啶
    • 頭孢曲松

9. 頭孢菌素類藥物市場依給藥途徑

  • 靜脈
  • 口服

第 10 章頭孢菌素類藥物市場（按劑型）

  • 膠囊
  • 注射
  • 粉末
  • 藥片

第 11 章頭孢菌素類藥物市場（依最終使用者）

  • 門診手術中心
  • 診所
  • 居家護理
  • 醫院

12. 頭孢菌素類藥物市場依分銷管道分類

  • 離線
  • 線上

第13章頭孢菌素類藥物市場應用

  • 淋病
  • 呼吸道感染疾病
    • 支氣管炎
    • 肺炎
  • 敗血症
  • 皮膚感染疾病
  • 尿道感染

14. 頭孢菌素類藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章頭孢菌素類藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 頭孢菌素類藥物市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • Teva Pharmaceutical Industries Ltd
    • Sandoz International GmbH
    • Viatris Inc.
    • Dr. Reddy's Laboratories Ltd
    • Sun Pharmaceutical Industries Ltd
    • Lupin Limited
    • Cipla Limited
    • Sanofi SA
Product Code: MRR-433AB1DC28F3

The Cephalosporin Drugs Market is projected to grow by USD 20.60 billion at a CAGR of 6.85% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 12.11 billion
Estimated Year [2025] USD 12.95 billion
Forecast Year [2032] USD 20.60 billion
CAGR (%) 6.85%

A strategic framing that positions cephalosporin therapeutics amid evolving clinical standards, supply pressures, and stakeholder incentives

Cephalosporin agents have remained a foundational component of antibacterial therapy for decades, adapting continuously to shifts in pathogen susceptibility, clinical practice, and supply chain realities. This introduction frames the therapeutic class within a contemporary context: the interplay of new regulatory expectations, evolving resistance patterns, and changing preferences in administration and dispensing. By situating cephalosporins within these converging forces, readers can appreciate why granular intelligence across drug classes, routes of administration, dosage forms, end-user settings, distribution channels, and clinical applications is essential for strategic decision-making.

Clinical stakeholders increasingly emphasize stewardship while balancing the need for rapid, effective therapy. Concurrently, manufacturers and distributors are navigating manufacturing complexities, raw material constraints, and pricing pressures. Policymakers and payers are introducing targeted interventions that influence formulary placement, procurement strategies, and reimbursement structures. Against this backdrop, the cephalosporin class is not static; it is actively shaped by prescriber behavior, emerging resistance, and logistical considerations that determine access and utilization.

This introduction sets the stage for the subsequent analysis by clarifying the scope and the analytical lenses applied across the study. It highlights the importance of integrating clinical, commercial, and operational perspectives to derive actionable conclusions. Readers will find a synthesis of clinical evidence, supply-side dynamics, and stakeholder incentives that collectively inform decisions about product development, portfolio management, and distribution strategies.

Key transformative forces reshaping cephalosporin therapeutics through diagnostics, regulatory rigor, and evolving distribution architectures

The cephalosporin landscape is undergoing transformative shifts driven by scientific innovation, regulatory emphasis on antimicrobial stewardship, and structural changes across the pharmaceutical supply chain. Novel diagnostic tools and rapid susceptibility testing influence prescribing at the point of care, enabling more targeted use of cephalosporins and reducing empirical broad-spectrum exposure where narrower agents suffice. Simultaneously, regulatory frameworks are tightening around antimicrobial stewardship metrics and quality control in manufacturing, prompting greater industry investment in compliance, traceability, and batch-level assurance.

On the commercial side, distribution models are shifting as digital channels and specialty logistics accelerate product reach to ambulatory surgical centers, homecare providers, and decentralized clinics. Investment in cold-chain infrastructure and packaging for injections and powders coexists with an increased emphasis on oral formulations to support outpatient therapy. These shifts also intersect with clinical practice: hospitals recalibrate formularies to reflect both efficacy and supply resilience, while prescribers weigh local resistance patterns when selecting agents.

Collectively, these changes reconfigure competitive dynamics, forcing incumbents to rethink portfolios and encouraging newcomers to pursue niche formulations or delivery systems. For decision-makers, the implication is clear: adaptability across manufacturing, regulatory affairs, and commercial operations will determine who capitalizes on the next wave of clinical and logistical demand.

How evolving United States tariff and trade policies exert cumulative pressures on cephalosporin supply chain resilience and procurement strategies

Tariff changes and trade policy adjustments instituted in recent periods have created notable ripple effects across pharmaceutical sourcing and distribution, particularly for products with complex supply chains such as cephalosporin antibiotics. Shifts in tariff schedules affecting active pharmaceutical ingredients and finished dosage forms change relative sourcing economics, prompting manufacturers to reassess supplier footprints, consider localization of certain production steps, or reconfigure import/export strategies to mitigate cost and lead-time impacts.

In response, contract manufacturers and brand owners have explored alternative procurement strategies including multi-sourcing, regionalizing supply flows, and increasing inventory buffers for critical inputs. Logistics partners have been asked to provide greater transparency on landed costs and timing, enabling procurement teams to model scenario-based decisions that balance cost, resilience, and regulatory compliance. Healthcare providers and group purchasing organizations are likewise re-evaluating supplier contracts and delivery terms to maintain continuity of care for inpatient and outpatient settings.

From a clinical perspective, the indirect effect of tariffs manifests as changes in formulary negotiations and procurement timelines, which can alter availability patterns for specific dosage forms and administration routes. The cumulative impact has been a heightened focus on supply chain risk management and sourcing agility, with stakeholders prioritizing partners that demonstrate secure, compliant, and cost-predictable supply arrangements. Going forward, organizations that integrate trade-policy awareness into product lifecycle planning and procurement strategies will be better positioned to preserve access and manage unit-cost volatility.

A multidimensional segmentation synthesis that links drug class, administration route, dosage form, end-user behavior, distribution channels, and clinical applications

A nuanced segmentation framework is essential for understanding where clinical demand, manufacturing complexity, and distribution economics converge within the cephalosporin class. Based on Drug Class, the analysis considers Fifth Generation, First Generation, Fourth Generation, Second Generation, and Third Generation agents, with the Third Generation examined in depth across Cefdinir, Cefixime, Cefotaxime, Ceftazidime, and Ceftriaxone. This drug-class granularity reveals divergent clinical roles: some generations maintain primary utility in community-acquired infections, while others serve critical roles in hospital-based and severe systemic infections.

Based on Route Of Administration, intravenous and oral modalities present different manufacturing and distribution considerations, with intravenous forms often demanding sterile production environments and more complex logistics, whereas oral forms favor broader outpatient access and retail distribution. Based on Dosage Form, capsules, injections, powders, and tablets each impose distinct formulation, stability, and packaging requirements that affect production timelines and supply-chain risk profiles. Based on End User, ambulatory surgical centers, clinics, homecare providers, and hospitals show varying procurement practices, reimbursement environments, and clinical protocols that influence product selection and inventory strategies.

Based on Distribution Channel, offline and online channels are reshaping how products reach prescribers and patients, influencing lead times, dispensing behaviors, and visibility into adoption trends. Based on Application, clinical demand is parsed across gonorrhea, respiratory tract infections, sepsis, skin infections, and urinary tract infections, with respiratory tract infections further distinguished by bronchitis and pneumonia subtypes. This multi-dimensional segmentation enables targeted assessment of where investment in supply chain improvements, clinical education, or formulation innovation will yield the highest operational and clinical returns.

Regional dynamics and regulatory nuances that determine access pathways, procurement behaviors, and distribution complexity across global territories

Regional dynamics exert a profound influence on clinical practice patterns, supply resilience, regulatory priorities, and commercial strategies across the cephalosporin landscape. In the Americas, healthcare systems emphasize centralized procurement mechanisms in hospitals and integrated delivery networks, while outpatient and retail channels continue to support broad access to oral formulations. Regulatory agencies in the region are increasingly focused on antimicrobial stewardship policies, affecting guideline-driven prescribing and formulary decisions that reflect evolving susceptibility profiles.

Europe, Middle East & Africa present a heterogeneous environment where regulatory frameworks, procurement modalities, and clinical guidelines diverge significantly across jurisdictions. This variation creates both challenges and opportunities: suppliers that tailor regulatory dossiers, quality assurances, and commercial strategies to regional expectations can access specialized segments such as hospital tenders and government procurement. Distribution complexity varies markedly across this combined region, with logistics providers needing to navigate diverse cold-chain requirements, import regulations, and local manufacturing incentives.

Asia-Pacific continues to be a dynamic arena shaped by rapid expansion of outpatient care, increased investment in local manufacturing capacity, and distinct clinical patterns that influence product preference. Countries in the region show a growing appetite for oral cephalosporins in community settings, alongside expanding hospital demand for injectable forms as tertiary care capacity grows. Across all regions, cross-border collaboration, regulatory harmonization efforts, and investments in supply-chain transparency will play critical roles in enabling consistent access to essential cephalosporin therapies.

Competitive and operational profiles of key industry participants emphasizing manufacturing resilience, regulatory compliance, and distribution agility

Industry participants in the cephalosporin space display a range of strategic priorities that reflect their positions across the product lifecycle, from active ingredient suppliers to finished-dosage manufacturers and specialized distributors. Leading players invest in sterile manufacturing capabilities, quality assurance systems, and regulatory affairs teams to support intravenous and injectable portfolios, while others focus on high-volume oral formulations optimized for ambulatory care and retail distribution. Strategic partnerships and contract manufacturing relationships remain central to scaling supply quickly and maintaining product continuity.

Competitive differentiation arises from several capabilities: robust compliance with evolving regulatory standards, flexible multi-site production to mitigate regional disruptions, and integrated cold-chain logistics for temperature-sensitive products. Companies that combine clinical engagement programs with real-world evidence generation strengthen their formulary positioning and prescriber trust. Additionally, investments in digital distribution channels and e-pharmacy partnerships have enabled some firms to expand their reach into online dispensing while preserving pharmacovigilance and patient support services.

For organizations evaluating competitors or potential partners, core considerations include the depth of sterile and non-sterile manufacturing capacity, the robustness of quality management systems, the ability to navigate regional regulatory environments, and the agility of distribution networks to support hospitals, clinics, ambulatory surgical centers, and homecare providers. Those that align operational excellence with targeted clinical support and flexible commercial models are best positioned to capture sustained clinical adoption.

Actionable industry priorities that enhance supply resilience, clinical alignment, and omnichannel distribution to preserve access and support stewardship

Industry leaders should pursue a set of actionable priorities that strengthen supply resilience, align clinical value with product positioning, and optimize commercial pathways to support appropriate access. First, enhance supply-chain flexibility by diversifying sources for critical inputs, qualifying regional contract manufacturers, and instituting scenario-based inventory planning that anticipates trade-policy and logistics disruptions. This approach minimizes single-point dependencies and supports consistent availability across hospitals, clinics, ambulatory surgical centers, and homecare settings.

Second, invest in sterile-production capabilities and quality assurance to support intravenous and injectable formats, while simultaneously optimizing oral dosage formulations for outpatient adherence and dispensing. Integrate clinical engagement programs that communicate appropriate use for indications such as gonorrhea, respiratory tract infections including bronchitis and pneumonia, sepsis, skin infections, and urinary tract infections, thereby reinforcing stewardship objectives and improving prescriber confidence.

Third, adopt omnichannel distribution strategies that combine offline strength in institutional procurement with online platforms that enhance retail and home-delivery access. Leverage digital tools to improve demand visibility and to coordinate replenishment across distribution nodes. Finally, align commercial and regulatory teams to proactively address regional requirements across the Americas, Europe, Middle East & Africa, and Asia-Pacific, ensuring dossier readiness, pharmacovigilance compliance, and tailored market access strategies. These actions will collectively improve organizational readiness to respond to clinical, regulatory, and logistical shifts.

A rigorous mixed-methods approach combining stakeholder interviews, regulatory review, and scenario-based analysis to ensure actionable and reproducible insights

The research approach integrates primary and secondary intelligence streams to construct a comprehensive view of clinical, operational, and commercial drivers affecting cephalosporin therapies. Primary inputs include structured conversations with clinicians across acute and ambulatory settings, procurement professionals in hospitals and group purchasing organizations, regulatory affairs specialists, and logistics providers responsible for cold-chain and sterile-product distribution. These engagements provided direct insight into prescribing behavior, procurement constraints, and operational pain points.

Secondary analysis encompassed a rigorous review of regulatory guidance, clinical literature on antimicrobial stewardship and cephalosporin utilization, publicly available pharmacovigilance data, and trade policy notices affecting pharmaceutical imports and exports. Synthesis relied on cross-validation between qualitative insights from stakeholder interviews and quantitative indicators such as manufacturing capacity distributions, distribution channel adoption metrics, and application-level clinical prevalence patterns. Analytical frameworks emphasized scenario planning to assess supply chain sensitivities and regulatory contingencies.

Throughout the methodology, emphasis was placed on transparency, reproducibility, and relevance to decision-makers. Assumptions and sources were documented and stress-tested through sensitivity checks, while regional differences were explicitly modeled to ensure that conclusions remain applicable across diverse healthcare systems. This methodological rigor underpins the report's recommendations and ensures they are operationally actionable for commercial, clinical, and regulatory teams.

Conclusive synthesis highlighting the operational, regulatory, and clinical imperatives necessary to secure sustainable access to cephalosporin therapies

The cephalosporin therapeutic area sits at the intersection of clinical necessity and complex supply dynamics, demanding coordinated responses from manufacturers, distributors, clinical leaders, and policymakers. The analysis underscores that success in this space requires more than product availability; it requires resilient manufacturing, regulatory agility, clear clinical communication, and distribution networks that can adapt to both institutional procurement and expanding outpatient care models.

Investment in sterile production for injectable formulations, paired with optimization of oral dosage forms for outpatient access, supports a balanced portfolio responsive to both hospital and community needs. Strengthening supplier diversity and logistics transparency reduces vulnerability to trade-policy shifts and raw material constraints. Simultaneously, integrating stewardship-focused clinical engagement preserves therapeutic efficacy and supports appropriate utilization across indications including gonorrhea, respiratory tract infections, sepsis, skin infections, and urinary tract infections.

In conclusion, organizations that proactively align operational capabilities, regulatory readiness, and clinical outreach will be best positioned to maintain access while navigating the evolving landscape. The path forward hinges on strategic investment, disciplined execution, and collaborative approaches that bridge clinical imperatives with supply-chain realities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging fifth-generation cephalosporin candidates targeting multidrug resistant Gram-negative infections in hospital settings
  • 5.2. Strategic collaborations between pharmaceutical companies and biotech startups to accelerate novel cephalosporin antibiotic discovery
  • 5.3. Expansion of generic cephalosporin production in Asia Pacific driven by lower manufacturing costs and regulatory support
  • 5.4. Integration of antibiotic stewardship programs to optimize cephalosporin utilization and curb antimicrobial resistance trends
  • 5.5. Pipeline of combination therapies pairing cephalosporins with beta-lactamase inhibitors to overcome extended-spectrum resistant strains
  • 5.6. Government pricing and reimbursement reforms affecting access and affordability of advanced cephalosporin treatments globally

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cephalosporin Drugs Market, by Drug Class

  • 8.1. Fifth Generation
  • 8.2. First Generation
  • 8.3. Fourth Generation
  • 8.4. Second Generation
  • 8.5. Third Generation
    • 8.5.1. Cefdinir
    • 8.5.2. Cefixime
    • 8.5.3. Cefotaxime
    • 8.5.4. Ceftazidime
    • 8.5.5. Ceftriaxone

9. Cephalosporin Drugs Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral

10. Cephalosporin Drugs Market, by Dosage Form

  • 10.1. Capsule
  • 10.2. Injection
  • 10.3. Powder
  • 10.4. Tablet

11. Cephalosporin Drugs Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
  • 11.3. Homecare
  • 11.4. Hospitals

12. Cephalosporin Drugs Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Cephalosporin Drugs Market, by Application

  • 13.1. Gonorrhea
  • 13.2. Respiratory Tract Infections
    • 13.2.1. Bronchitis
    • 13.2.2. Pneumonia
  • 13.3. Sepsis
  • 13.4. Skin Infections
  • 13.5. Urinary Tract Infections

14. Cephalosporin Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cephalosporin Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cephalosporin Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Pfizer Inc.
    • 17.3.2. F. Hoffmann-La Roche Ltd
    • 17.3.3. Teva Pharmaceutical Industries Ltd
    • 17.3.4. Sandoz International GmbH
    • 17.3.5. Viatris Inc.
    • 17.3.6. Dr. Reddy's Laboratories Ltd
    • 17.3.7. Sun Pharmaceutical Industries Ltd
    • 17.3.8. Lupin Limited
    • 17.3.9. Cipla Limited
    • 17.3.10. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. CEPHALOSPORIN DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. CEPHALOSPORIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CEPHALOSPORIN DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIFTH GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIFTH GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIFTH GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIFTH GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIFTH GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIFTH GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFDINIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFDINIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFDINIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFDINIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFDINIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFDINIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFIXIME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFIXIME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFIXIME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFIXIME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFIXIME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFIXIME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFOTAXIME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFOTAXIME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFOTAXIME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFOTAXIME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFOTAXIME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFOTAXIME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTAZIDIME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTAZIDIME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTAZIDIME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTAZIDIME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTAZIDIME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTAZIDIME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTRIAXONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTRIAXONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTRIAXONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTRIAXONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTRIAXONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTRIAXONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GONORRHEA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GONORRHEA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GONORRHEA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GONORRHEA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GONORRHEA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY BRONCHITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY BRONCHITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY BRONCHITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY BRONCHITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY BRONCHITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY BRONCHITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PNEUMONIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PNEUMONIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PNEUMONIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PNEUMONIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PNEUMONIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SEPSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SEPSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SEPSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SEPSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SEPSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SEPSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 321. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 322. AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 326. ASIA-